Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79 (NASDAQ:BVS)
· seekingalpha.com
Bioventus Q3 2026 earnings: revenue guidance cut on BGS weakness, EPS reaffirmed, and Q4 acceleration expected.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...